TREOS Bio Partners with Charit Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer
News Source : Financial Post
News Summary
- Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer.
- PolyPEPI1018 is TREOS Bio’s lead off-the-shelf multi-peptide active cancer immunotherapy designed to convert immunologically “cold” tumors to ‘hot’ tumors.
- The therapy has demonstrated encouraging clinical activity across three Phase I/II trials (44 patients in total) in advanced MSS CRC.
Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, addressing 85% of CRC cases with limited treatm [+6053 chars]